NUVILEX ENTERS MARIJUANA FOLD
After establishing its "Medical Marijuana Sciences" subsidiary, Nuvilex (NVLX.PK) shares soared to an 80% gain pretty much instantly. Nuvilex's subsidiary is focused on using cannabinoids in biotechnology and pharmaceuticals. Nuvilex ultimately is a life sciences and biotech firm, so it comes equipped with experience in conducting clinical trials in this emerging healthcare space. In its Phase II trial for treating pancreatic cancer, Nuvilex found no adverse immunological events. The product approximately doubled the median survival time compared to the current gold standard. There was also a doubling in the number of survivors past 1 year compared to those using Gemzar. And it was this effective with only one-third of the normal chemotherapy dose used to treat other cancers. Nuvilex is now looking to release cannabinoid-based therapeutics that treats glioblastoma multiform, an aggressive form of brain cancer.
Nuvilex's decision to enter the high-growth medical marijuana market at the same time that it advances a cancer drug into late-stage clinical trials is particularly well-timed, because it legitimizes the pot industry. One of the biggest headwinds medical marijuana stocks face is the reality that many individuals still, inaccurately, see them as producers of pseudo-scientific treatments that will never outcompete biopharmaceuticals. As a biotech company with already promising clinical data, Nuvilex thus largely removes this kind of mindset in a way that positions the stock for strong returns.
After establishing its "Medical Marijuana Sciences" subsidiary, Nuvilex (NVLX.PK) shares soared to an 80% gain pretty much instantly. Nuvilex's subsidiary is focused on using cannabinoids in biotechnology and pharmaceuticals. Nuvilex ultimately is a life sciences and biotech firm, so it comes equipped with experience in conducting clinical trials in this emerging healthcare space. In its Phase II trial for treating pancreatic cancer, Nuvilex found no adverse immunological events. The product approximately doubled the median survival time compared to the current gold standard. There was also a doubling in the number of survivors past 1 year compared to those using Gemzar. And it was this effective with only one-third of the normal chemotherapy dose used to treat other cancers. Nuvilex is now looking to release cannabinoid-based therapeutics that treats glioblastoma multiform, an aggressive form of brain cancer.
Nuvilex's decision to enter the high-growth medical marijuana market at the same time that it advances a cancer drug into late-stage clinical trials is particularly well-timed, because it legitimizes the pot industry. One of the biggest headwinds medical marijuana stocks face is the reality that many individuals still, inaccurately, see them as producers of pseudo-scientific treatments that will never outcompete biopharmaceuticals. As a biotech company with already promising clinical data, Nuvilex thus largely removes this kind of mindset in a way that positions the stock for strong returns.
